Back to search
FDAFDA · Food and drugs·Recall number D-0269-2022

Fexofenadine HCl 60 mg/ Pseudoephedrine HCl 120 mg Extended Release Tablets USP Allergy & Congestion, 20 Tablets, Distributed by: Dr. Reddy's Laboratories, Inc. Princeton, NJ 08540, NDC 43598-823-14.

Published December 15, 2021 · Recall initiated: November 12, 2021

Summary

FDA records drug Class III recall D-0269-2022, published December 15, 2021 and initiated November 12, 2021. Recalling firm: Dr. Reddy's Laboratories, Inc.; Status: Terminated; Reported quantity: 5016 cartons; Lot: Lot #: AC2103329F, Exp 1/2023. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed dissolution specifications

What to do

Letter

Get an email if FEXOFENADINE HCL AND PSEUDOEPHEDRINE HCI has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
FEXOFENADINE HCL AND PSEUDOEPHEDRINE HCI
Manufacturer
Dr. Reddy's Laboratories, Inc.
Distributor
USA Nationwide.
Lot
Lot #: AC2103329F, Exp 1/2023
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Fexofenadine HCl 60 mg/ Pseudoephedrine HCl 120 mg Extended Release Tablets USP Allergy & Congestion, 20 Tablets, Distributed by: Dr. Reddy's Laboratories, Inc. Princeton, NJ 08540, NDC 43598-823-14. recalled?

Yes. FDA published recall D-0269-2022 on December 15, 2021. Reported hazard: Failed dissolution specifications

What should I do if I have this product?

Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: FEXOFENADINE HCL AND PSEUDOEPHEDRINE HCI.